Avidity Biosciences's total assets for Q3 2025 were $2.13B, an increase of 55.90% from the previous quarter. RNA total liabilities were $247.94M for the fiscal quarter, a 40.67% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.